Anafen Injection 10 mg/mL (Canada)

This page contains information on Anafen Injection 10 mg/mL for veterinary use.
The information provided typically includes the following:
  • Anafen Injection 10 mg/mL Indications
  • Warnings and cautions for Anafen Injection 10 mg/mL
  • Direction and dosage information for Anafen Injection 10 mg/mL

Anafen Injection 10 mg/mL

This treatment applies to the following species:
Manufacturer: Merial

Ketoprofen Injection 10 mg/mL

Ketoprofen 5, 20 mg Tablets

Nonsteroidal Antiinflammatory Analgesic for Dogs and Cats

For Veterinary Use Only

D.I.N. 02150999, 02150964, 02150980

Active Ingredient

Each mL of Anafen® Injection contains 10 mg of ketoprofen in an aqueous solution with L-Arginine 7.2 mg: Benzyl Alcohol 1% as a preservative; Sodium chloride 4.2 mg; and Citric Acid added as necessary to adjust pH.

Each white scored Anafen® Tablet contains:

Ketoprofen

5 mg

Ketoprofen

20 mg

Pharmacology

Ketoprofen, 2-(3-benzoyl phenyl) propionic acid, is a nonsteroidal antiinflammatory drug (NSAID) belonging to the propionic acid subclass of carboxylic acid derivative nonsteroidal antiinflammatory drugs. Other propionic acid derivative NSAIDS include ibuprofen, naproxen and fenoprofen. Ketoprofen exerts three main pharmacological effects which are common to all NSAIDS: antiinflammatory, analgesic and antipyretic. The primary mechanism of action is inhibition of prostaglandin synthesis through interference with the cyclo-oxygenase pathway of arachidonic acid metabolism. Ketoprofen has been shown to have potent activity against acute, subacute and chronic inflammation in the classical models of inflammation.

Ketoprofen has a high affinity for inflamed tissue leading to greater concentrations and longer residence time in inflamed tissues than in plasma. For this reason, ketoprofen can be administered once a day to dogs and cats despite the relatively short plasma half-life (approximately 5 hours in dogs and 1.6 hours in cats). Onset of activity is rapid with peak plasma concentrations occurring within 1/2 hour after parenteral administration and within 1 hour of oral administration. Anafen® tablets are virtually completely absorbed from the gastrointestinal tract of dogs and cats and can be given without regard to meal time.

Toxicity: Anafen® has a wide margin of safety in dogs and cats. At deliberate overdoses up to 10 times the recommended dose and up to 90 days of administration in dogs, gastro-intestinal disturbances such as diarrhea, anorexia, melena, and weight loss were mild and self-limiting. At higher doses up to 36 mg/kg/day toxic effects were observed clinically and histologically on the gastrointestinal tract, the liver and the kidneys. Cats treated with up to 4 times the recommended dose of Anafen® did not exhibit clinical signs of gastrointestinal toxicity and necropsy revealed comparable lesions in both Anafen® and untreated control cats.

The incidence of side effects observed in clinical efficacy studies involving 432 dogs and 112 cats was: vomiting - dogs 6%, cats 10.7%: abnormal stool (e.g. diarrhea, melena) - dogs 2%, cats 2.6%; decreased appetite - dogs 0.7%; increased thirst - dogs 0.7%. A direct drug relationship could not be established in most cases.

Anafen Injection 10 mg/mL Indications

Dogs and Cats: for the alleviation of inflammation, lameness and pain due to osteoarthritis, hip dysplasia, disc disease, spondylosis, panosteitis, trauma, and related musculoskeletal diseases; for the management of post-surgical pain; for the symptomatic treatment of fever. When inflammation and/or fever are associated with a primary infectious process, Anafen® should be used in conjunction with appropriate antiinfective therapy.

Contraindications

Do not use in animals with gastroduodenal ulcers, impaired liver and/or kidney function, and coagulation disorders. Do not use in animals with known hypersensitivity to NSAIDS. Do not use in breeding animals as effects on fertility and reproductive function in dogs and cats have not been studied. Avoid inadvertent intra-arterial injection. Do not mix Anafen® with other drugs in the same syringe.

Dosage and Administration

Dogs: Administer Anafen® Injection at a dose of 2 mg/kg (0.2 mL/kg) body weight by intramuscular, intravenous or subcutaneous injection for one day, and continue with Anafen® Tablets per os at a lower maintenance dose of 1 mg/kg once a day for four more days. Cats: Administer Anafen® Injection at a dose of 2 mg/kg (0.2 mL/kg) body weight by subcutaneous injection for one day, and continue with Anafen® Tablets per os at a lower maintenance dose of 1 mg/kg once a day for four more days. In severe cases, the parenteral loading dose of 2 mg/kg can be given for up to three consecutive days.

Precautions

Gastrointestinal, renal and hepatic function should be monitored periodically in animals on prolonged Anafen® therapy, and a drug withdrawal period should be instituted prior to elective surgery.

How Supplied

Injection: Anafen® Injection is supplied in 20 mL multiple dose vials packaged in individual boxes. Tablets: Anafen® 5 and 20 mg Tablets are supplied in aluminum foil blister packs containing 10 tablets per strip, and packaged one strip or five strips per colour coded carton.

Storage Conditions: Store at controlled room temperature 15 °C-25 °C (59 °F-77 °F). Protect from exposure to direct sunlight.

Warning

Keep this and all medication out of the reach of children.

Manufactured by: MERIAL Canada, Inc. - 20000 Clark Graham - Baie d’Urfé - QC, H9X 4B6

037 002935 - A0101

NAC No.: 11820043

MERIAL CANADA INC.
20000 CLARK GRAHAM, BAIE D'URFÉ, QC, H9X 4B6
Telephone:   514-457-1555
Order Desk:   888-637-4251 (888-MERIAL1)
Fax:   514-457-1175
Website:   www.merial.ca
Email:   service.canada@merial.com
Every effort has been made to ensure the accuracy of the Anafen Injection 10 mg/mL information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.

Copyright © 2014 North American Compendiums. Updated: 2014-12-03

(web1)